Press release
Lipodystrophy Pipeline 2025: Pioneering Clinical Developments by 8+ Global Leaders - DelveInsight | Highlighting Regeneron Pharmaceuticals, Entos Pharmaceuticals, Rejuvenate Bio
Lipodystrophy Pipeline 2025
With lipodystrophy becoming increasingly prevalent worldwide and contributing to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is growing demand for safer and more effective therapies. DelveInsight reports that over eight pharmaceutical and biotech companies are actively developing more than eight therapeutic candidates targeting lipodystrophy. These treatments are at various stages of clinical and preclinical development, reflecting strong innovation and a commitment to addressing this significant public health challenge.
DelveInsight's "Lipodystrophy Pipeline Insight 2025" report offers a comprehensive review of the current R&D landscape, including clinical trial progress, emerging therapies, mechanisms of action, competitive dynamics, and major company initiatives. The report is an essential resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving lipodystrophy therapeutics market and the innovations shaping its future.
Explore the Cutting-Edge Landscape of Lipodystrophy Drug Development [https://www.delveinsight.com/report-store/lipodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Key Takeaways from the Lipodystrophy Pipeline Report
*
DelveInsight's Lipodystrophy pipeline report highlights a dynamic landscape, with more than eight companies actively developing multiple therapies for lipodystrophy treatment.
*
On March 25, 2025, the FDA approved the F8 formulation of tesamorelin, marketed as EgriftaWR Trademark , for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
*
As of January 24, 2025, Phase 3 recruitment is ongoing for congenital generalized lipodystrophy, with primary completion expected around March 8, 2027. Additionally, a Phase 2 study for Familial Partial Lipodystrophy (LEAP) completed primary data collection in April 2024, targeting overall completion by June 30, 2025.
*
Leading companies in the lipodystrophy space, including Regeneron Pharmaceuticals, Entos Pharmaceuticals, Rejuvenate Bio, and others, are actively developing new therapies to advance treatment options. Promising candidates in the pipeline include Mibavademab and several others, reflecting ongoing innovation in the field.
Lipodystrophy Overview:
Lipodystrophy syndromes are a group of rare disorders characterized by abnormal or selective loss of body fat, often accompanied by low circulating leptin levels, which can result in complications such as osteosclerosis. This significant fat loss contributes to metabolic dysfunction, particularly insulin resistance, and can lead to related conditions including type 2 diabetes, dyslipidemia, fatty liver, acanthosis nigricans, polycystic ovarian syndrome, and hypertension. The two main genetic forms are congenital generalized lipodystrophy (CGL), an autosomal recessive disorder marked by near-total absence of body fat from infancy, and familial partial lipodystrophy (FPLD), an autosomal dominant condition characterized by gradual fat loss from the limbs during late childhood or adolescence.
Patients with lipodystrophy may present a wide range of clinical features, such as increased metabolic rates, accelerated bone growth, and prominent abdominal appearance due to abnormal fat distribution. Other possible signs include intellectual disability, thickened or darkened skin (acanthosis nigricans), and early-onset puberty. These symptoms are often accompanied by metabolic complications like insulin resistance, hyperglycemia, fatty liver, dyslipidemia, and elevated cardiovascular risk, all contributing to long-term health challenges.
The pathophysiology of lipodystrophy involves impaired adipocyte development and defective lipid storage, frequently associated with mutations in genes such as AGPAT2 and BSCL2, which are essential for fat cell function and lipid regulation. In certain variants, such as gynoid lipodystrophy, vascular changes, increased capillary pressure, and glycosaminoglycan deposition can cause tissue hypoxia and enlargement of fat cells. Acquired forms of lipodystrophy may result from external factors, including antiretroviral therapy for HIV or autoimmune conditions, leading to abnormal fat distribution, hormonal imbalances, and reduced secretion of key adipokines like leptin and adiponectin.
Download the Lipodystrophy sample report to know in detail about the Lipodystrophy treatment market [https://www.delveinsight.com/sample-request/lipodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Lipodystrophy Pipeline Analysis
The Lipodystrophy pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Lipodystrophy Market.
*
Categorizes Lipodystrophy therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Lipodystrophy drugs under development based on:
*
Stage of development
*
Lipodystrophy Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Lipodystrophy Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Lipodystrophy Licensing agreements
*
Funding and investment activities supporting future Lipodystrophy market advancement.
Unlock key insights into emerging Lipodystrophy therapies and market strategies here: https://www.delveinsight.com/report-store/lipodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Lipodystrophy Emerging Drugs
*
Mibavademab: Regeneron Pharmaceuticals
REGN4461 (Mibavademab) is an antibody that acts as a leptin receptor (LEPR) agonist, developed by Regeneron Pharmaceuticals for the treatment of generalized lipodystrophy. The therapy is currently in Phase III clinical trials, evaluating its efficacy in patients with both generalized and familial partial lipodystrophy.
Lipodystrophy Pipeline Therapeutic Assessment
Lipodystrophy Assessment by Product Type
- Mono
- Combination
- Mono/Combination
Lipodystrophy By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Lipodystrophy Assessment by Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Lipodystrophy Assessment by Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download sample pages to get an in-depth assessment of the emerging Lipodystrophy therapies and key Lipodystrophy companies [https://www.delveinsight.com/sample-request/lipodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. Lipodystrophy Current Treatment Patterns
4. Lipodystrophy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Lipodystrophy Late-Stage Products (Phase-III)
7. Lipodystrophy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Lipodystrophy Discontinued Products
13. Lipodystrophy Product Profiles
14. Lipodystrophy Key Companies
15. Lipodystrophy Key Products
16. Dormant and Discontinued Products
17. Lipodystrophy Unmet Needs
18. Lipodystrophy Future Perspectives
19. Lipodystrophy Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Lipodystrophy pipeline reports offerings [https://www.delveinsight.com/report-store/lipodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lipodystrophy-pipeline-2025-pioneering-clinical-developments-by-8-global-leaders-delveinsight-highlighting-regeneron-pharmaceuticals-entos-pharmaceuticals-rejuvenate-bio]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lipodystrophy Pipeline 2025: Pioneering Clinical Developments by 8+ Global Leaders - DelveInsight | Highlighting Regeneron Pharmaceuticals, Entos Pharmaceuticals, Rejuvenate Bio here
News-ID: 4227942 • Views: …
More Releases from ABNewswire
Pheochromocytoma Pipeline 2025: Key Clinical Developments by Leading Global Inno …
DelveInsight's, "Pheochromocytoma - Pipeline Insight, 2025," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Pheochromocytoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With Pheochromocytoma increasingly prevalent worldwide and contributing to comorbidities such as diabetes,…
Presbyopia Pipeline 2025: Innovative Clinical Developments by Leading Global Com …
DelveInsight's, "Presbyopia - Pipeline Insight, 2025" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As presbyopia becomes increasingly prevalent worldwide and is associated with comorbidities such…
Primary Ciliary Dyskinesia Pipeline 2025: Groundbreaking Clinical Advancements b …
DelveInsight's, "Primary Ciliary Dyskinesia - Pipeline Insight, 2025," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Primary Ciliary Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As Primary Ciliary Dyskinesia (PCD) increasingly impacts populations…
Periodontal Disease market is projected to experience significant growth by 2032 …
Periodontal Disease market is projected to experience significant growth by 2032, driven by major players such as Dentsply Sirona Inc., Envista Holdings Corporation, A-dec Inc., J. Morita Corp., Straumann Group, BIOLASE, BEGO GmbH & Co. KG, Ultradent Products, and Yoshida Dental.
Key factors contributing to this growth include the rising prevalence of Periodontal Disease, increased investments in R&D, and the introduction of novel and emerging therapies during the forecast period 2019-2032.
Additionally,…
More Releases for Lipodystrophy
Lipodystrophy Market Detailed Industry Report Analysis 2025-2034
Introduction
Lipodystrophy is a rare and complex metabolic disorder characterized by the abnormal distribution or complete absence of body fat. Patients may present with severe insulin resistance, hypertriglyceridemia, fatty liver disease, and heightened cardiovascular risks, in addition to visible physical changes. The psychological and quality-of-life burden is substantial, making effective treatment critical.
Historically, management relied on symptomatic control through insulin sensitizers, lipid-lowering drugs, and lifestyle interventions. The approval of metreleptin (a recombinant…
Lipodystrophy Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Lipodystrophy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lipodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Lipodystrophy Research. Learn more about our innovative pipeline…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
HIV Associated Lipodystrophy Syndrome Market 2017-2025 | TMR Research
Global HIV Associated Lipodystrophy Syndrome Market: Snapshot
HIV-associated lipodystrophy is a syndrome that are found in human immune-deficiency virus (HIV)-infected patients who are being administered with active antiretroviral medications for the treatment of HIV infection. Patients have lipohypertrophy, an abnormal central fat accumulation or lipoatrophy, localized loss of fat tissue, or a mixed clinical presentations representing both. The complex morphological signs associated with lipodystrophy syndrome inhibits our understanding of the etiology…
Lipodystrophy Therapeutics- Pipeline Analysis 2018 | Ionis Pharmaceuticals, Inc. …
Lipodystrophy is a rare medical condition which involves problems with fat production, usage, and storage. It is categorized into two types; congenital and acquired lipodystrophy.
Download the sample report @ https://www.pharmaproff.com/request-sample/1077
Congenital lipodystrophies include congenital generalized lipodystrophy, familial partial lipodystrophy, and marfanoid progeroid lipodystrophy syndrome; while acquired lipodystrophy includes acquired partial lipodystrophy, acquired generalized lipodystrophy, centrifugal abdominal lipodystrophy, lipoatrophia annularis, localized lipodystrophy and HIV-associated lipodystrophy.
Get the detailed analysis @ https://www.pharmaproff.com/report/lipodystrophy-therapeutics-pipeline-analysis
The…
HIV-associated Lipodystrophy Market Research Report 2017
Changes in body fat concentration, affecting people with HIV, is known as HIV-associated lipodystrophy. The exact causes of this condition is currently unknown, but research suggests that this disorder can occur either due to HIV infection or as a consequence of side effects associated with drugs used in HIV infection treatment, such as Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), etc. The lipodystrophy condition is characterized by metabolic abnormalities,…
